TRIDENT

Transformative Research in Diabetic Nephropathy

TRIDENT

Transformative Research in Diabetic Nephropathy

Redefining diabetic kidney disease through human kidney tissue.TRIDENT is a multi-center, public–private research consortium that integrates kidney biopsy pathology, multi-omic profiling, and longitudinal clinical outcomes to enable precision diagnostics and targeted therapies for diabetic kidney disease.

By anchoring discovery in human kidney tissue and following patients over time, TRIDENT identifies disease-driving mechanisms, stratifies biological risk, and accelerates translation from biology to patient care.

[For Researchers & Industry]  [For Patients & Families]

TRIDENT at a glance

• Study type: Prospective, biopsy-anchored observational cohort

• Scope: Kidney pathology, genomics, transcriptomics, spatial biology, proteomics, urine and blood biomarkers

• Cohort: Adults with diabetes undergoing clinically indicated kidney biopsy

• Follow-up: Longitudinal clinical outcomes and kidney function trajectories

• Consortium: >22 academic medical centers across North America with industry partners

• Platform: TRIDENT 1.0 (disease mechanisms) and TRIDENT 2.0 (therapeutic modulation)

• Output: Peer-reviewed publications, validated biomarkers, and translational datasets